102 Chapter 4 tivity. In contrast, receiver operating characteristic curve analysis for disease-free survival showed an association (P = 0.018) between an average A2H2-3 immunoreactivity ≤2% and disease-free survival using the area under the curve as a performance measure (results not shown). Evaluation of MET protein status across the tissue microarray and its association with prognosis Using the definitions for MET protein status, it can be stated that 36 cancers are negative for MET (23%), 14 cancers are positive for the MET decoy receptor (9%), and 106 cancers are positive for transmembranous C-terminal MET (68%, Supplementary Fig. 6). Univariable survival analyses reveals that patients with cancers negative for MET immunoreactivity perform significantly worse than those with cancers positive for transmembranous C-terminal MET in terms of disease-free survival (HR = 1.84; 95% CI, 1.16–2.93 and P = 0.010; Fig. 6a; Supplementary Table 6) and overall survival (HR = 2.00; 95% CI, 1.24–3.23 and P = 0.005; Fig. 6b; Supplementary Table 7). The decoy receptor did not significantly contribute to the model for either disease-free survival or overall survival. Fig. 6: Kaplan–Meier curves. a Disease-free survival for all patients, stratified by MET receptor status. b Overall survival for all patients, stratified by MET receptor status.
RkJQdWJsaXNoZXIy MTk4NDMw